Appendix XLI

Board of Trustees

210 Bricker Hall 190 North Oval Mall Columbus, OH 43210-1388

> Phone (614) 292-6359 Fax (614) 292-5903 trustees.osu.edu

SUMMARY OF ACTIONS TAKEN

February 23, 2021 - Wexner Medical Center Board Meeting

Voting Members Present by Zoom Virtual Meeting:

Leslie H. WexnerStephen D. SteinourKristina M. Johnson (exAbigail S. WexnerRobert H. Schottensteinofficio)Cheryl L. KruegerW.G. "Jerry" JurgensenHarold L. Paz (ex officio)Hiroyuki FujitaCindy HilsheimerBruce A. McPheron (ex officio)John W. ZeigerGary R. Heminger (ex officio)Michael Papadakis (ex officio)

Members Absent:

N/A

PUBLIC SESSION

The Wexner Medical Center Board convened for its 37th meeting on Wednesday, February 23, 2021, virtually over Zoom. Board Secretary Jessica A. Eveland called the meeting to order at 1:00 p.m.

Item for Action

 Approval of Minutes: No changes were requested to the November 18, 2020, meeting minutes; therefore, a formal vote was not required, and the minutes were considered approved.

Items for Discussion

 Chancellor's Report: Dr. Harold Paz began his report with a moment of silence for those whose lives have been lost during the COVID-19 pandemic. The day prior to the board meeting, the United States hit a grim milestone with more than 500,000 deaths as a result of the pandemic.

Dr. Paz continued his report by sharing significant achievements that had occurred around the Wexner Medical Center since the board's November meeting. *Forbes* recognized the Wexner Medical Center as No. 14 out of 500 employers nationally on its 2021 list of "America's Best Large Employers," ahead of such employers as Netflix, Microsoft and the University of Michigan. The medical center ranked second in the nation on this list among health systems, behind only the Mayo Clinic. This recognition indicates that not only does the medical center have an exceptional depth and breadth of talent, but its employees also feel supported and would recommend the medical center as a top place to work.

Dr. Paz also congratulated Daniel Lesman, a College of Medicine student in biomedical science, who was named a Rhodes Scholar in November. This honor marked the first time Ohio State has had a student earn a Rhodes in three consecutive years. The university has had nine Rhodes Scholars total.

The Blue Ridge Institute for Medical Research released its 2020 rankings — a compilation of National Institutes of Health (NIH) rankings for U.S. medical schools. In 2020, in spite of the pandemic, our direct NIH funding increased by 16% to reach \$160.2 million, which is a record for the College of Medicine. We have two top-10 programs and a total of four top-20 programs in the nation, highlighted by our Department of Surgery, which ranked No. 4 in the nation. We ranked No. 39 overall, which was a jump of nine spots in just two years. Additionally, the College of Nursing earned its highest NIH funding ever, rising to No. 13 in the country, up from No. 16 the year prior.

Items for Discussion (continued)

The Centers for Disease Control and Prevention recognized Ohio State with its Million Hearts designation. Million Hearts is a national, federal initiative to prevent 1 million heart attacks and strokes within five years. We are the first health system in the Midwest and one of just four in the nation to receive this honor. Dr. Paz thanked College of Nursing Dean Bernadette Melnyk for her leadership in spearheading this initiative with leaders across the medical center to develop innovative, evidence-based programs, such as a free online interprofessional education module that has been implemented in all 50 states, as well as the Ask a Buckeye Nurse program that provides heart healthy education in local barber shops.

Dr. Paz noted that our response to COVID-19 has been driven by our commitment as a land-grant institution to share our knowledge and expertise in order to keep our communities as safe and healthy as possible. And Ohio State is at the forefront of the global pandemic response. Dr. Paz shared that the media coverage from our vaccine distribution launch alone led to more than 2,100 positive media stories around the world, with a combined audience of 2.1 billion individuals. Dr. Paz thanked the entire team that was charged with coordinating our COVID-19 vaccination distribution at the Schottenstein Center – specifically Ryan Haley and Crystal Tubbs, who have provided extraordinary leadership to a large group of faculty, staff and volunteers. He also thanked the exceptional team of Buckeyes who care for our patients every day, as well as the community members and local businesses who have donated countless meals and more than \$1.9 million since the start of the pandemic to directly support the wellbeing of our healthcare workers on the frontlines. He then closed his report by sharing a video that highlighted the team's dedication and achievements. As Buckeyes, we have continued to rise to the occasion and meet every challenge that this pandemic has thrown our way.

3. <u>COVID-19 Report</u>: Dr. Peter Mohler, chief scientific officer; Elizabeth Seely, chief administrative officer; and Dr. Andrew Thomas, chief clinical officer; gave an overview of the Wexner Medical Center's COVID-19 research and innovation efforts, clinical testing efforts that have resulted in nearly 500,000 tests so far, the vaccination program at the Schottenstein Center, and more details on the innovative monoclonal antibody treatment protocol for COVID-19 patients.

Ohio State is truly a leader in its trials for therapeutics that are now being used in clinics, and also in research that identified two new viral strains in the United States. These newly identified strains pose significant health risks related to increased infectivity, and the medical center is testing the impact of current therapeutics on these new strains. The first vaccination in Ohio took place at the Wexner Medical Center on December 14, 2020. As of February 11, 2021, a total of 45,626 doses had been administered. The Schottenstein Center opened its vaccination site to the public on January 19.

Also as of February 11, the medical center had infused 1,200 patients with monoclonal antibody treatments (Bamlanivimab and Regeneron), with the first infusion at the medical center taking place on November 18, 2020. The advantage of this treatment is that it helps to greatly reduce the risks for patients who are at high-risk for severe disease and hospitalization.

(See Attachment XLII for background information, page 1062)

4. <u>James Cancer Hospital Report</u>: Dr. William Farrar, CEO of the James Cancer Hospital, touched on how the pandemic negatively impacted cancer screenings and treatments in 2020, which can lead to worse outcomes and delayed diagnosis. In the U.S., studies have found that an estimated 22 million cancer screenings were cancelled or missed between March and June of 2020, and 35 percent of American adults missed a scheduled cancer screening during the pandemic. To address this concerning issue, the James has started a marketing campaign to promote cancer prevention and screenings across the region and state. The James has also joined 75 other cancer centers across the country to support Re-engage in Cancer Care, a program that encourages cancer prevention and screening efforts.

Items for Discussion (continued)

In spite of the pandemic, the James has had a variety of successes and accomplishments since the last board meeting. Several years ago, the Alliance of Dedicated Cancer Centers – which includes the PPS-Exempt Cancer Hospitals in the country – recognized the need for a program that addresses end-of-life care and increases communication between clinicians and patients. Under the direction of Dr. Jillian Rustin and in collaboration with several faculty and staff members, the medical center has instituted a four-point plan to improve goal-concordant care and enhance communication through end-of-life care.

Research at the James, while disrupted by the pandemic, has continued in earnest. In 2020, there were 104 new cancer-specific grants at the Comprehensive Cancer Center. We were awarded \$53.3 million from the NCI, which ranks us No. 15 in terms of NCI funding compared to other campus programs. For comparison, in 2018 we received \$40 million and ranked No. 25. We also have opened 114 new clinical research studies and enrolled 785 patients in therapeutic trials. In 2020, cancer center members also had 877 publications in peer-reviewed journals, including 178 in journals with an impact factor of 10 or higher.

In December, the James launched the statewide Turning the Page on Breast Cancer in Ohio, an initiative focused on breast cancer education, facilitating access to genetics counseling and ensuring appropriate screening and follow-up for abnormalities and treatment for Black women who are at an increased risk for breast cancer. Also in December, the James received a \$10 million gift from the Paula and Rodger Riney Family Foundation to establish the Riney Family Foundation Myeloma Center for Advanced Research Excellence. Led by Dr. Don Benson, the center will explore potential new treatments using specific molecular targets.

Finally, Dr. Farrar also highlighted the work of Pelotonia. During unprecedented circumstances and challenges, the Pelotonia community came together in 2020 and raised \$10.5 million after moving from an in-person event to a virtual platform. Pelotonia 2021 launched on February 18 and announced plans for a socially distanced ride the weekend of August 6-8.

(See Attachment XLIII for background information, page 1080)

5. Wexner Medical Center Financial Report: Wexner Medical Center CFO Mark Larmore reported on the financial results for the health system as of December 31, 2020, which was running nearly \$25 million ahead of budget with revenue growth of approx. 12.5 percent over the prior year. The combined Wexner Medical Center results, consisting of the health system, College of Medicine and OSU Physicians, was running \$39 million ahead of budget with revenue growth of 7.1 percent. Mr. Larmore also noted that, while overall cash has gone down on the medical center's balance sheet, this is an expected result of the medical center's plan to (among other things) move forward with its capital programs during the pandemic.

(See Attachment XLIV for background information, page 1087)

Items for Action

6. Resolution No. 2021-69, Recommend Approval to Enter Into/Increase Professional Services and Enter Into/Increase Construction Contracts

Synopsis: Authorization to enter into/increase professional services and construction contracts, as detailed in the attached materials, is proposed.

WHEREAS in accordance with the attached materials, the university desires to enter into/increase professional services contracts and enter into construction contracts for the following projects; and

	Prof. Serv. Approval Requested	Construction Approval Requested	Total Requested	
James – Halcyon Linear Accelerator	\$0.2M	\$5.7M	\$5.9M	Auxiliary Funds

WHEREAS in accordance with the attached materials, the university desires to increase construction contracts for the following project; and

	Construction	Total	
	Approval	Requested	
	Requested		
Martha Morehouse Facility Improvements	\$37.0M	\$37.0M	Auxiliary Funds

NOW THEREFORE

BE IT RESOLVED, That the Wexner Medical Center Board hereby approves and proposes that the professional services and construction contracts for the projects listed above be recommended to the University Board of Trustees for approval; and

BE IT FURTHER RESOLVED, That the President and/or Senior Vice President for Business and Finance be authorized to enter into/increase professional services and construction contracts for the projects listed above in accordance with established University and State of Ohio procedures, all actions to be reported to the board at the appropriate time.

(See Appendix LVIII for background information, page 1488)

Items for Action (continued)

7. Resolution No. 2021-70 Ratification of Committee Appointments 2021-2022

BE IT RESOLVED, That the Wexner Medical Center Board hereby approves that the ratification of appointments to the Quality and Professional Affairs Committee for 2021-2022 are as follows:

Quality and Professional Affairs Committee

Cheryl L. Krueger, Chair
ALAN A. STOCKMEISTER, VICE CHAIR
ANAND SHAH

Harold L. Paz
Bruce A. McPheron
Michael Papadakis
David P. McQuaid
Andrew M. Thomas
David E. Cohn
Elizabeth Seely
Minka Schofield
Amit Agrawal
Scott A. Holliday
lahn Gonsenhauser
Jacalyn Buck
Kristopher M. Kipp
Abigail S. Wexner (ex officio)

Action: Upon the motion of Mr. Wexner, seconded by Ms. Hilsheimer, the board adopted the foregoing motion for resolution No. 2021-70 by unanimous voice vote with the following members present and voting: Mr. Wexner, Mrs. Wexner, Ms. Krueger, Dr. Fujita, Mr. Stockmeister, Mr. Zeiger, Mr. Shah, Mr. Steinour, Mr. Schottenstein, Mr. Jurgensen, Ms. Hilsheimer, Dr. Johnson, Dr. Paz, Dr. McPheron and Mr. Papadakis. Mr. Heminger was not present for this vote.

Items for Action (continued)

8. Resolution No. 2021-71 Amendments to the Bylaws of The Ohio State University Wexner Medical Center Board

Synopsis: Approval of the attached amendments to the *Bylaws of The Ohio State University Wexner Medical Center Board* is proposed.

WHEREAS pursuant to 3335-1-09 (C) of the Administrative Code, the rules and regulations for the university may be adopted, amended or repealed by a majority vote of the University Board of Trustees at any regular meeting of the board; and

WHEREAS a periodic review of the board's bylaws is a governance best practice; and

WHEREAS the last revisions to the *Bylaws of The Ohio State University Wexner Medical Center Board* took place in November 2019:

NOW THEREFORE

BE IT RESOLVED, That the Wexner Medical Center Board hereby recommends approval by the University Board of Trustees of the attached amendments to the *Bylaws of The Ohio State University Wexner Medical Center Board*.

(See Appendix L for background information, page 1322)

Action: Upon the motion of Mr. Wexner, seconded by Dr. Paz, the board approved the foregoing motions for resolutions No. 2021-69 and 2021-71 by majority voice vote with the following members present and voting: Mr. Wexner, Mrs. Wexner, Mrs. Krueger, Dr. Fujita, Mr. Stockmeister, Mr. Zeiger, Mr. Shah, Mr. Steinour, Mr. Schottenstein, Mr. Jurgensen, Ms. Hilsheimer, Dr. Johnson, Dr. Paz, Dr. McPheron and Mr. Papadakis. Mr. Heminger was not present for this vote.

EXECUTIVE SESSION

It was moved by Mr. Wexner, and seconded by Mr. Zeiger, that the board recess into executive session to consider business-sensitive trade secrets required to be kept confidential by federal and state statutes, to consult with legal counsel regarding pending or imminent litigation, and to discuss personnel matters involving the appointment, employment and compensation of public officials, which are required to be kept confidential under Ohio law.

A roll call vote was taken, and the board voted to go into executive session with the following members present and voting: Mr. Wexner, Mrs. Wexner, Ms. Krueger, Dr. Fujita, Mr. Stockmeister, Mr. Zeiger, Mr. Shah, Mr. Steinour, Mr. Schottenstein, Mr. Jurgensen, Ms. Hilsheimer, Dr. Johnson, Dr. Paz, Dr. McPheron and Mr. Papadakis. Mr. Heminger was not present for this vote.

The board entered executive session at 1:48 p.m. and adjourned at 5:02 p.m.



Peter Mohler, PhD

Chief Scientific Officer, The Ohio State University Wexner Medical Center Vice Dean for Research, The Ohio State University College of Medicine

Research and Discovery

Nearly half a million COVID RNA Diagnostic Tests performed to date at OSUWMC

Continue to be national leader in trials for therapeutics that are now in clinic. Treatment trials
Monoclonal antibodies:ACTIV-2/A5401

Outpatient: ACTIV-2/A5401(Eli Lilly)

Inpatient: Regeneron 2066

Oral agent: AT-527 (ATEA)

Oral agent: AT-527 (ATEA)

Convalescent plasma (multiple studies)


Prevention trials-

Monoclonal antibodies: Anti-Spike SARS-CoV-2 (REGN)


Vaccine: AZD1222

X axis: Time in months over 2020


Discovery of two new viral strains in United States at Ohio State



COH.20G/677H December 2020





COH.20G/501Y December 2020



Tu et al (Jones Lab) bioRxiv preprint doi: https://doi.org/10.1101/2021.01.12.426407

'OSU Re-defining Global COVID Transmission: Creation of novel 501Y strain





Incidence

Status: Paper under peer review | First online: 11-01-2021 | Last update: 11-01-2021 Authors: Carl A.B. Pearson*, Timothy W Russell, Nicholas Davies, Adam J Kucharski, CMMID COVID-19 working group, W John Edmunds & Rosalind M Eggo.

Testing the impact on current therapeutics on new viral strains

Print/Online Coverage



The Washington Post



New York Eimes







Researchers in Ohio find preliminary evidence of two virus variants that may be more contagious.

New væant of COVID-19 discovered in Ohio



Two new variants of the coronavirus that may be more contagious brake been determed in Ohio, researchers announced on Wecheeday, Evidence for both variants is still preliminary, other experts contribed, and warrants further study. "As we sequence more, we will find more variants and we will see

Scientists at Ohio State University have discovered a new varient of the virus that causes COVID-19 — and also found the evolution of another US strain with three gene mutations not previously seen tagether


CORONAVIRUS

The researchers at Ohio State's Womer Medical Center and College of Medicine sold the new variant cerries a mutation identical to the UK strain, but it

more mutations," said Emma Hodcroft, a molecular epidemiologis at the University of Bern in Switzerfand. "But very few mutations we are looking at today have never appeared before."

2 new coronavirus variants that likely originated in US identified in Ohio: researchers

000000



One of the new strains was identified in a single patient in the state, "so researchers do not ye know the prevalence of the strain in the population" according to Dhio State Weamer Medical

Travel Opinion

comp-19 nesounces Your questions answ...

U.s. CAPITOL NIOTS Database of arrests

COVID-19 BY STATE
Track vaccinations

First, vaccinate as many people as possible—and fast. The snail's crawl at which vaccine rollout is proceeding in the United States simply won't cut it, especially now that researchers at Ohio State University have reported To avoid being crushed by the incoming tide, we'll need to do two things the discovery of a new SARS-CoV-2 variant in Columbus, Ohio, People mutate, and evolve new means of surpassing our defenses. These new must be vaccinated not just to prevent them from getting sick, but to reduce the number of opportunities SARS-CoV-2 has to experiment, properties are ones we cannot anticipate-only observe and react to.

list of mutations such as those discovered in the United Kingdom and South Africa,

11's here. We found it. Weld Gagnon, associate professor of cheming many like the Weld Gagnon, associate professor of cheming many biochemistry at SU, said. Tit's definitely home-grown and widesprend, and we're the first to characterize it."

It could be more easily transmissible than other variants, and its impert or wordens is uncertain, the university said.

Also, scientists at The Ohio State University have discovered a new Najant of SARS-Cov-2, the virus that causes COVID-19. The new variant carque a mutation

identical to the strain in the United Kingdom, but it likely arose in **Ayr**us strain already present in the United States.

COVID-19 virus that is specific to and dominant in the U.S., adding to the growing

A research team at Southern Illinois University discovered a new variant of the

need to be prospecting the entirety of the genome, as well as the entirety of picture. That has cost us dearly. We can't afford to make the same mistake the biosphere, for alterations that encourage immune modulation. And we Second, expand current efforts to sequence and survey new variants. We need to be prepared to adapt our vaccines to an adapting virus, as we do with seasonal flu. Over the course of the pandemic, not nearly enough emphasis has been placed on thinking longer term about the bigger with these variants. Not when we know exactly what to do to protect



United States, researchers announced Wednesday. The new mutations challenge scien Here are some significant developments: nutations similar to those seen in South Africa and the Scientists at The Ohio State University documented

prompting scientists to learn more about how those variants might be causing a worldwid

New York Gay, Andrew M. Cuomo (D) confirmed Wed

Center Says Researchers Discovered New Variant BRIEF-Ohio State University's Wexner Medical Of Covid-19 Virus In Columbus, Ohio

Ohio researchers say they've identified two new Covid strains ikely originating in the U.S. Jan 13 (Reuters) - Ohio State University's Wexner Medical Center

* OHIO STATE UNIVERSITY'S WEXNER MEDICAL CENTER - RESEARCHERS DISCOVER NEW VARIANT OF COVID-19 VIRUS IN COLUMBUS, OHIO

IDENTICAL TO U.K. STRAIN. BUT LIKELY AROSE IN VIRUS STRAIN ALREADY * WEXNER MEDICAL CENTER - NEW VARIANT CARRIES A MUTATION

TV - National and International Coverage



FOX & WJW CLEVELAND























































































































































































RESEARCHERS DISCOVER NEW VIRUS VARIANTS IN OHIO, ONE SIMILAR TO UK STRAIN

PANDEMIC'S DEADLIEST DAY 4327 COVID FATALITIES, 18J SAYS VACCINE SHOWS PROMISE.










RESEARCHERS IDENTIFY TWO NEW VIRUS VARIANTS LIKELY ORIGINATED IN THE U.S.















Andrew Thomas, MD, MBA, FACP

Chief Clinical Officer, The Ohio State University Wexner Medical Center Senior Associate Vice President for Health Sciences

Ohio COVID-19 Vaccination **Program**

First vaccination in Ohio at the Wexner Medical Center on Monday, December 14

February 23-25, 2021, Board of Trustee

1,161,056

Click County to Filter Metrics 55,013

Statewide: Vaccine Status By Total and % of Population

Phase 1A:

- Healthcare personnel
- Nursing facility residents and staff
 - EMS providers

1071


Phase 1B:

- Began January 18
- Elderly patients
- congenital/neurological disabilities and other illnesses with increased risk of severe disease/death Adult patients with
- Student-facing K-12 teachers and staff









VACCINE

OSUWMC COVID-19 Vaccination Program

Data as of February 11:

45,626 total doses administered

1A Vaccination Program:

16,417 first doses administered

13,866 second doses administered

1B Vaccination Program:

Schottenstein Center vaccination site opened to public on Jan 19

13,866 first doses administered

1,477 second doses administered

Multiple ways to schedule:

OSU MyChart

Televox automated calls

Provider offices

614-688-VAXX vaccine hotline

Ohio State tests out COVID vaccine clinic at Schottenstein Center

Max Filby The Columbus Dispatch Published 2:35 p.m. ET Jan. 15, 2021





Pfizer

OSUWMC COVID-19 Vaccination Program

The New York Times

U.S. Starts Vaccine Rollout as High-Risk Health Care Workers Go First



WSJ VIDEO

First U.S. Covid-19 Vaccines Roll Out DR. IAHN GONSENHAUSER





















= DR. FAUCI ON WHEN HE'LL GET THE CORONAVIRUS VACCINE AND MISSING



Elizabeth Seely, MHA, FACHE Chief Administrative Officer, Hospital Division

THE OHIO STATE UNIVERSITY

WEXNER MEDICAL CENTER

27

2/1/2021

1/1/2021 1,325 12/1/2020 11/1/2020 TOTAL CENSUS 10/1/2020 COVID vs Non-COVID Census **COVID vs. Non-COVID Census** COVID_CENSUS 9/1/2020 8/1/2020 NON COVID_CENSUS 7/1/2020 6/1/2020 5/1/2020 4/1/2020 1,200 1,400 1,000 ⊚ 1075 009 200 400

February 23-25-2021, Board of Trustees Meetings

Monoclonal Antibody Treatment

Total patients infused as of February 11, 2021 = 1,200

DECEMBER FDA Emergency **NOVEMBER 21** Authorization – Regeneron First patient infused November Bamlanivimab received **NOVEMBER '20 NOVEMBER 16** First supply of PDA Emergency Use Authorization – **NOVEMBER 9** Bamlanivimab

16 (first in Central Ohio) at East

Hospital, Wallace Auditorium

Regeneron - First **DECEMBER 4**

Wallace Auditorium patient infused at East Hospital,



Wallace Auditorium - after


Nallace Auditorium - before

OSUWMC Monoclonal Antibody Treatment

Admission Rate for COVID patients at high-risk for severe disease*:

- Placebo = 10%
- Monoclonal treatment = 3%
- prevent an admission = 14.3 infusions Number needed to treat (NNT) to







- OSU Monoclonal Treatments since November 2020***E = 1,200

 Estimated # of admissions with no treatment* = 120
 Estimated # of admissions with treatment* = 36
 Actual number of admissions from OSU infusions = 343



- Estimated # of "avoided" admissions = 77
- Estimated # of "avoided" patient days** = 991 days
- possible due to avoided COVID admissions** = 149 Estimated # of additional non-COVID admissions

^{*} Based on published clinical data

^{**} Based on OSUWMC LOS data for COVID and non-COVID care

^{***} Infusions through February 11, 2021

Patient Verbatim:

"The infusion was a gamesurrender after five nights saved my life. Thank you again." infusion of bamlanivimab of intense, 103-degree, changer for me. I was punishing fevers. The reaching a point of



Faculty and Staff Support – Buckeye Paws

:

buckeyepaws
The Ohio State University Wexner Medical Center

buckeyepaws
The Ohio State University Wexner Medical Center

The Columbus Bispatch

Q

Ш

Sign In Subscribe

Buckeye Paws Program helps Wexner healthcare workers de-stress

LIFESTYLE

Megan Henry The Columbus Dispatch

Published 6:03 a.m. ET Jan. 2, 2021



Buckeye Paws therapy dog Shiloh, a 3-year-old golden retriever, stands with his owner, Mary Justice, and fellow therapy dogs in front





Z



19

0:36¹²/61:29



measurement Implement a framework

Establish expectations care, including priority regarding goals of populations for

communication

electronic health


records

documentation in *Communications supports the delivery Implement a formal of goal concordant skills training program that

Create structured

goals of care

The James





cancer screenings were cancelled or missed between March and June of In the United States, studies have found that an estimated 22 million

43% of patients have missed routine preventive appointments due to COVID-19 fears.

1082

35% of American adults had a cancer screening scheduled during the pandemic and missed it. 76 cancer centers, including The James, have signed the Re-engage in Cancer Care letter.

ons emphasize need ely treatment amid New Disgnostic Center Speeds Up Cancer Diagnostic Provides Immediate Access The provide Cancer organizations emphasize need for screening, timely treatment amid pandemic

urging Americans to make cance C ADD TOPIC TO EMAIL ALERTS A coalition of 76 cancer organiz

В

Ohio State joins nationwide effort to resume cancer screening,

f Truste

The James

s across the country to endorse the resumption or ening and treatment during the ongoing COVID-19 the public that cancer still poses a major threat to salth. They note that acting as soon as its safely obtain preventative cancer screenings and neede however, can lead to better outdomes in the future.

rday, February 1, 2021 12:00

reatment

THE OHIO STATE UNIVERSITY COMPREHENSIVE CANCER CENTER

cancer screenings to improve chances nedical officer for The James and a gyr

Acobert W. Cartson, M.D., chief executive officer of NCCN notes that when the pandemic first hit the United States, a short delay in care was an appropriate choice for many cancer types. However, he says, the balance of risk has shifted significantly.

Source: NCCN; American Cancer Society

Several strategies are being used to direct interested women to a website to determine if they are at increased risk for breast cancer.

The James at Ohio State is addressing breast cancer disparitie

The James

In December the OSUCCC-James received a \$10

million gift from the Paula and Rodger Riney Foundation to establish the Riney Family Foundation Myeloma Center for Advanced

Research Excellence (Myeloma CARE).


Paul and Rodger Riney

The James

THE OHIO STATE UNIVERSITY
WEXNER MEDICAL CENTER

potential new treatments using specific molecular

Opened 114 new clinical research studies	178 of the 877 articles published were in journals with impact factor >10
Received \$53.3M from the NCI	Published 877 articles in peer-reviewed journals
Awarded 104 new cancer-specific grants	Enrolled 785 patients on therapeutic trials



Pelotonia 2021 launched on February 18th. The ride will take place the weekend of August 6-8, 2021.

New Routes and a New Experience: Mew routes:


Saturday: 20, 50, 80, and 100-mile options Sunday: 20, 50, and 100-mile options Saturday and Sunday (2-day options): 180 and 200 miles only

the Franklin County Health Department and will continue to assess capacity levels throughout the spring and We will follow all guidance and protocols as outlined by

Together, We Achieve Achieve Meetings \$10,502,362 raise and a strict pants and a strict pants of the stric 822,362 miles

The James

Attachment XLIV



Wexner Medical Center Financial Report Public Session

February 23, 2021

The Ohio State University Health System

Consolidated Statement of Operations For the YTD ended: December 31, 2020 (in thousands)

OSUHS							
	Actual		Budget	Act-Bud	Budget % Var	Prior	PY % Var
OPERATING STATEMENT					3	5	5
Total Revenue	\$ 1,758,8	385	\$ 1,758,885 \$ 1,726,573 \$ 32,312	\$ 32,312	1.9%	1.9% \$ 1,679,604	4.7%
Operating Expenses							
Salaries and Benefits	751,230	230	758,690	7,460	1.0%	736,437	-2.0%
Resident/Purchased Physician Services	62,634	334	62,379	(255)	-0.4%	58,285	-7.5%
Supplies	201,111	7	188,177	(12,934)	%6.9-	184,054	-9.3%
Drugs and Pharmaceuticals	232,952	352	221,789	(11,163)	-5.0%	213,907	-8.9%
Services	163,108	108	169,695		3.9%	164,370	0.8%
Depreciation	86,535	535	86,539	4	%0.0	87,662	1.3%
Interest	14,8	14,993	14,993	•	%0.0	16,205	7.5%
Shared/University Overhead	23,6	23,953	26,562	2,609	8.6	24,934	3.9%
Medical Center Investments	91,982	382	91,982	•	%0.0	77,886	-18.1%
Total Expense	1,628,498	498	1,620,806	(7,692)	%5.0-	1,563,740	-4.1%
Excess of Revenue over Expense	\$ 130,387		\$ 105,767	\$ 24,620	23.3% \$	\$ 115,864	12.5%

The Ohio State University Wexner Medical Center

Combined Statement of Operations For the YTD ended: December 31, 2020 (in thousands)

	Αc	Actual	Δ.	Budget	₹ >	Act-Bud Variance	Budget % Var	Prior Year	r PY % Var	
OPERATING STATEMENT										
Total Revenue	\$2,2	\$2,277,189	\$2,	\$2,246,664	↔	30,525	1.4%	1.4% \$2,183,158		4.3%
Operating Expenses										
Salaries and Benefits	1,1	1,179,990	τ,	1,202,936		22,946	1.9%	1,140,679		-3.4%
Resident/Purchased Physician Services		62,634		62,379		(255)	-0.4%	58,285		-7.5%
Supplies	6	224,640	.,	210,740		(13,900)	%9 ·9-	206,705		-8.7%
Drugs and Pharmaceuticals	6	237,608	.,	226,378		(11,230)	-5.0%	219,506		-8.2%
Services	Ò	245,419	.,	260,302		14,883	5.7%	250,273		1.9%
Depreciation	-	101,078		100,869		(209)	-0.2%	100,360		-0.7%
Interest/Debt		20,358		20,361		က	0.0%	21,770		6.5%
Shared/University Overhead		23,953		26,565		2,612	8.6	15,958		-50.1%
Other Operating Expense		20,372		20,036		(336)	-1.7%	27,672		26.4%
Medical Center Investments		14,167		8,493		(5,674)	%8 '99-	4,749	9 -198.3%	.3%
Total Expense	2,1	2,130,219	2,	2,139,059		8,840	0.4%	2,045,957		-4.1%
Excess of Revenue over Expense	8	146,970	€	107,605	↔	39,365	36.6% \$	\$ 137,201		7.1%
Financial Metrics										
Integrated Margin Percentage		6.5%		4.8%		1.7%	34.8%	6.3	6.3% 2.	2.7%
Adjusted Admissions		64,816		68,100		(3,284)	-4.8%	69,316		-6.5%
Operating Revenue per AA	49	26,957	₩	25,169	↔	1,788	7.1%	\$ 24,096		11.9%
Total Expense per AA	₩.	23,895	₩	22,591	↔	(1,304)	-5.8%	\$ 21,551		-10.9%

The Ohio State University Wexner Medical Center

Combined Balance Sheet As of: December 31, 2020 (in thousands)

	Δ	December 2020		June 2020		Change
Cash	↔	1,728,587	\$	1,770,078	€9-	(41,491)
Net Patient Receivables		409,612		378,653		30,959
Other Current Assets		594,904		562,701		32,203
Assets Limited as to Use		422,276		421,698		578
Property, Plant & Equipment - Net		1,929,894		1,782,453		147,441
Other Assets		504,595		466,250		38,345
Total Assets	⇔	5,589,868	\$	5,381,833	€	208,035
Current Liabilities	₩.	827,584 \$	↔	781,864	↔	45,720
Other Liabilities		139,062		134,798		4,264
Long-Term Debt		634,350		665,906		(31,556)
Net Assets - Unrestricted		3,253,239		3,114,561		138,678
Net Assets - Restricted		735,633		684,705		50,928
Liabilities and Net Assets	₩	5,589,868	s	5,381,833	ક્ક	208,035

This Balance sheet is not intended to conform to Generally Accepted Accounting Principles. Different accounting methods are used in each of these entities and no eliminating entries are included.